Kane Biotech Inc. (KNBIF)
| Previous Close | 0.0939 |
| Open | 0.0939 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.0939 - 0.0939 |
| 52 Week Range | 0.0420 - 0.1228 |
| Volume | |
| Avg. Volume | 5,367 |
| Market Cap | 12.38M |
| Beta (5Y Monthly) | 0.55 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Kane Biotech to Host Investor Webinar
What the sale of STEM Animal Health means for Kane going forward – Thursday April 18th, 2024 at 4:15pm Eastern TimeWINNIPEG, Manitoba, April 16, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane”) announces that it will be hosting a webinar on Thursday April 18th, 2024 at 4:15pm Eastern Time. Marc Edwards, Kane's President & CEO, will share his thoughts on what the sale of STEM Animal Health, which should ultimately net Kane more than $13 million CND, means for Kane as
- GlobeNewswire
Kane Biotech Announces Closing of the Sale of STEM Animal Health to Dechra Veterinary Products
An important step in Kane becoming a market leader in the growing high-value wound care and dermatological marketsWINNIPEG, Manitoba, April 15, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane”) announces that, it has completed the sale of its interest in STEM Animal Health Inc. to Dechra Veterinary Products, Inc. for US $8,000,000, plus net cash held in STEM (estimated at CND $600,000) and a working capital adjustment (estimated at CND $350,000) (the “Transaction”). O
- GlobeNewswire
Kane Biotech Announces Agreement in Principle for the Sale of its Interest in STEM Animal Health
Transaction will strengthen balance sheet and refocus companyWINNIPEG, Manitoba, April 11, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces today that it has reached an agreement in principle for the sale of its entire interest (the “Interest”) in STEM Animal Health Inc. (“STEM”) to a third party multi-national pharmaceutical company (the “Purchaser”) on a cash-free debt-free basis for US $8,000,000 (the “Transaction”), subject to a
